{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:14:58Z","timestamp":1776150898129,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1097\/md.0000000000012102","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T08:43:45Z","timestamp":1538210625000},"page":"e12102","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia"],"prefix":"10.1097","volume":"97","author":[{"given":"Jun","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Fen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210309","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2337\/diacare.24.12.2091","article-title":"Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic\/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project","volume":"24","author":"Niskanen","year":"2001","journal-title":"Diabetes Care"},{"key":"R2-10-20210309","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-10-20210309","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3324\/haematol.2015.139105","article-title":"Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia","volume":"101","author":"Ossenkoppele","year":"2016","journal-title":"Haematologica"},{"key":"R4-10-20210309","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"R5-10-20210309","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.beha.2016.10.003","article-title":"Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?","volume":"29","author":"Estey","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"key":"R6-10-20210309","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.2016.150326","article-title":"Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia","volume":"102","author":"Mohty","year":"2017","journal-title":"Haematologica"},{"key":"R7-10-20210309","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2040620717703012","article-title":"Vosaroxin in relapsed\/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape","volume":"8","author":"Sedov","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"R8-10-20210309","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/annonc\/mdv205","article-title":"Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology\/Oncology (OSHO) and the Study Alliance Leukemia (SAL)","volume":"26","author":"Thiel","year":"2015","journal-title":"Ann Oncol"},{"key":"R9-10-20210309","first-page":"1113","article-title":"Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review)","volume":"27","author":"Van den Neste","year":"2005","journal-title":"Int J Oncol"},{"key":"R10-10-20210309","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ajh.23544","article-title":"Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients <\/=60 years with newly diagnosed acute myeloid leukemia","volume":"88","author":"Nazha","year":"2013","journal-title":"Am J Hematol"},{"key":"R11-10-20210309","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.23862","article-title":"Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?","volume":"90","author":"Freyer","year":"2015","journal-title":"Am J Hematol"},{"key":"R12-10-20210309","first-page":"183","article-title":"The guidelines for diagnosis and treatment of acute myelogenous leukemia (relapserefractory) in China (2017).","volume":"38","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R13-10-20210309","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mrgentox.2005.01.012","article-title":"Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor","volume":"583","author":"Hajji","year":"2005","journal-title":"Mutat Res"},{"key":"R14-10-20210309","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-4-46","article-title":"A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Wei","year":"2011","journal-title":"J Hematol Oncol"},{"key":"R15-10-20210309","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/bjc.1996.621","article-title":"Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines","volume":"74","author":"Lehne","year":"1996","journal-title":"Br J Cancer"},{"key":"R16-10-20210309","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1034\/j.1600-0609.2002.01598.x","article-title":"Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro","volume":"68","author":"Szmigielska-Kaplon","year":"2002","journal-title":"Eur J Haematol"},{"key":"R17-10-20210309","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clml.2014.06.005","article-title":"Phase I\/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia","volume":"15","author":"Abbi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R18-10-20210309","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/10428190903096719","article-title":"Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome","volume":"50","author":"Wu","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R19-10-20210309","first-page":"487","article-title":"Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells","volume":"118","author":"Mai","year":"2005","journal-title":"Chin Med J (Engl"},{"key":"R20-10-20210309","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/1042819021000035608","article-title":"Purine nucleoside analogues in the treatment of myleoid leukemias","volume":"44","author":"Robak","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R21-10-20210309","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fonc.2014.00093","article-title":"Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy","volume":"4","author":"Liongue","year":"2014","journal-title":"Front Oncol"},{"key":"R22-10-20210309","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"key":"R23-10-20210309","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J Clin Oncol"},{"key":"R24-10-20210309","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","article-title":"Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens","volume":"35","author":"Price","year":"2011","journal-title":"Leuk Res"},{"key":"R25-10-20210309","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00277-016-2774-z","article-title":"Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia","volume":"95","author":"Park","year":"2016","journal-title":"Ann Hematol"},{"key":"R26-10-20210309","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"R27-10-20210309","first-page":"4601","article-title":"Influence of clofarabine on transcriptional activity of PTEN, APC, RARB2, ZAP70 genes in K562 cells","volume":"30","author":"Majda","year":"2010","journal-title":"Anticancer Res"},{"key":"R28-10-20210309","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1042\/bj3590537","article-title":"Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria","volume":"359","author":"Marzo","year":"2001","journal-title":"Biochem J"},{"key":"R29-10-20210309","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/74994","article-title":"Mitochondrial control of cell death","volume":"6","author":"Kroemer","year":"2000","journal-title":"Nat Med"},{"key":"R30-10-20210309","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0006-2952(02)01486-7","article-title":"The effects of cladribine and fludarabine on DNA methylation in K562 cells","volume":"65","author":"Wyczechowska","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"R31-10-20210309","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.ejca.2015.06.117","article-title":"The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia","volume":"51","author":"Stumpel","year":"2015","journal-title":"Eur J Cancer"},{"key":"R32-10-20210309","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"key":"R33-10-20210309","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1517\/13543780903071038","article-title":"Cladribine: not just another purine analogue?","volume":"18","author":"Spurgeon","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"R34-10-20210309","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1182\/blood.V84.10.3429.3429","article-title":"Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000012102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:24:31Z","timestamp":1620962671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201809280-00010"}},"subtitle":["A retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":34,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000012102","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}